rexigen has been researched along with Diabetes Mellitus, Type 2 in 1 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabrera Pérez, LC; Correa Basurto, J; Cruz, A; Gómez López, M; Hernández Zavala, AA; Miliar García, Á; Padilla-Martínez, II; Rosales Hernández, MC | 1 |
1 other study(ies) available for rexigen and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Design, synthesis, molecular docking and in vitro evaluation of benzothiazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Amphetamines; Animals; Benzothiazoles; Catalytic Domain; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Molecular Docking Simulation; Obesity; Rats; Rats, Zucker | 2020 |